Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL2781385 | 1.00 | ALDH1A1 (0.47) | ALDH1A1LMNAOR51E2TP53USP2 | |
| Alanine SCHEMBL15323960 | 0.87 | OR51E2 (0.40) | ALDH1A1LMNAOR51E2TP53USP2 | |
| Alanine SCHEMBL15322553 | 0.87 | PAX8 (0.41) | ALDH1A1LMNAOR51E2TP53USP2 | |
| Alanine SCHEMBL20610135 | 0.86 | SLC22A6 (0.50) | LMNAOR51E2USP2SLCO1B1TDP1 | |
| Alanine SCHEMBL15323596 | 0.84 | TDP1 (0.53) | OR51E2TP53USP2SLCO1B1SLC7A5 | |
| Alanine SCHEMBL15323593 | 0.84 | TDP1 (0.53) | OR51E2TP53USP2SLCO1B1SLC7A5 | |
| Glycerin SCHEMBL11364524 | 0.83 | LMNA (0.53) | ALDH1A1LMNAOR51E2TP53USP2 | |
| Glycerin SCHEMBL1838800 | 0.83 | LMNA (0.53) | ALDH1A1LMNAOR51E2TP53USP2 | |
| Lactic Acid SCHEMBL15512248 | 0.83 | TP53 (0.65) | ALDH1A1LMNAOR51E2TP53USP2 | |
| Glycerin SCHEMBL2442337 | 0.83 | LMNA (0.53) | ALDH1A1LMNAOR51E2TP53USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506384-B1 | Assaying biological fluid sample from subject having symptoms of active tuberculosis for presence of early antibodies specific for a 27 kDa mycobacterial tuberculosis protein named MPT51 | NEW YORK UNIVERSITY | 2003-01-14 | — | — | US | claimed |
| US-6245331-B1 | Early detection of mycobacterial disease | NEW YORK UNIV. MEDICAL CENTER | 2001-06-12 | — | — | US | claimed |
| CN-108865918-B | Method for marking viable gram-positive bacteria and cell walls thereof | 中国科学院微生物研究所 | 2022-01-07 | — | — | CN | disclosed |
| CN-108865918-A | A method of the gram-positive bacterium of label survival and its cell wall | 中国科学院微生物研究所 | 2018-11-23 | — | — | CN | disclosed |
| CN-105579064-B | The active Inhibitors of anti-acid fast bacteria medicine, the screening technique of anti-acid fast bacteria medicine and WecA and its ortholog are used in combination | 公益财团法人微生物化学研究会 | 2018-11-13 | — | — | CN | disclosed |
| CN-108348510-A | Benzylamine-containing heterocyclic compounds and compositions useful against mycobacterial infections | M·J·米勒 | 2018-07-31 | — | — | CN | disclosed |
| CN-105579064-A | Combined anti-acid-fast bacterial agent, screening method for anti-acid-fast bacterial agents, and activity inhibitor of WecA or ortholog thereof | MICROBIAL CHEM RES FOUND | 2016-05-11 | — | — | CN | disclosed |
| EP-1567266-B1 | INTEGRATED SOLID-PHASE HYDROPHILIC MATRIX CIRCUITS AND MICRO-ARRAYS | EPOCAL INC (CA) | 2015-10-28 | — | — | EP | disclosed |
| US-7807182-B2 | Early detection of mycobacterial disease using peptides | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-20090280140-A1 | Early detection of mycobacterial disease using peptides | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2009-11-12 | — | — | US | disclosed |
| US-7201833-B2 | Integrated solid-phase hydrophilic matrix circuits and micro-arrays | EPOCAL INC. (CA) | 2007-04-10 | — | — | US | disclosed |
| EP-0952849-A4 | EARLY DETECTION OF MYCOBACTERIAL DISEASE | UNIV NEW YORK (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2004050243-A1 | INTEGRATED SOLID-PHASE HYDROPHILIC MATRIX CIRCUITS AND MICRO-ARRAYS | EPOCAL INC. (CA) | 2004-06-17 | — | — | WO | disclosed |
| US-20030127333-A1 | Integrated solid-phase hydrophilic matrix circuits and micro-arrays | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003012395-A2 | EARLY DETECTION OF MYCOBACTERIAL DISEASE USING PEPTIDES | NEW YORK UNIVERSITY (US) | 2003-02-13 | — | — | WO | disclosed |
| US-6506384-B1 | Assaying biological fluid sample from subject having symptoms of active tuberculosis for presence of early antibodies specific for a 27 kDa mycobacterial tuberculosis protein named MPT51 | NEW YORK UNIVERSITY | 2003-01-14 | — | — | US | disclosed |
| US-6245331-B1 | Early detection of mycobacterial disease | NEW YORK UNIV. MEDICAL CENTER | 2001-06-12 | — | — | US | disclosed |
| EP-0952849-A1 | EARLY DETECTION OF MYCOBACTERIAL DISEASE | NEW YORK UNIVERSITY (US) | 1999-11-03 | — | — | EP | disclosed |
| WO-1998029132-A9 | EARLY DETECTION OF MYCOBACTERIAL DISEASE | — | 1998-10-29 | — | — | WO | disclosed |
| WO-1998029132-A1 | EARLY DETECTION OF MYCOBACTERIAL DISEASE | NEW YORK UNIVERSITY (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280140-A1 | Early detection of mycobacterial disease using peptides | MICA, TAP1, TMEM41B | ALDH1A1 4659/4885LMNA 3830/4885OR51E2 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.